University of Pittsburgh

University of Arizona

National Institutes of Health, a Component of the US Dept. of Health & Human Services

University of Virginia

University of California

The Johns Hopkins University

Arizona Board of Regents, a Body Corporate

Musc Foundation for Research Development

Prolx Pharmaceuticals Corporation

The Brigham and Women's Hospital, Inc.

Sepracor, Inc.

Proix Pharmaceutical Corp.

Peter Wipf

John S Lazo

Donna Mary Huryn

Zhou Wang

Matthew G LaPorte

Erin M Skoda

Joel S Greenberger

Garth Powis

Joel Byron Nelson

David J Hackam

Michael Wayne Epperly

Mitchell P Fink

Valerian Kagan

Marie-Celine Frantz

Paul A Johnston

Mary Liang

Matthew D Neal

Yulia Tyurina

Chaemin Lim

Jingbo Xiao

Robert L Rice

Raffaele Colombo

April Cunningham

Paul David Robbins

James K Johnson

Laura J Niedernhofer

Wei Qian

Bennett Van Houten

Chhinder P Sodhi

Anthony J Kanai

Stephen D Meriney

Sodhi P Chhinder

Stephan Roever

Dennis Patrick Curran

William J Moore

Neal Green

Billy W Day

Carol A Feghali-Bostwick

Jennifer Rubin Grandis

Michelle Arkin

Patrick Joseph Pagano

Lynn D Kirkpatrick

Kean-Hooi Ang

Eric T Baldwin

Marina Kovaliov

Mark E Schurdak

Armido Studer

Masahide Hoshino

John Milligan

Julie Pamela Goff

R Jeffrey Neitz

Clifford Bryant

Stacie Bulfer

Maria Eugenia Cifuentes-Pagano

Marie Celine Frantz

Zhizhou Yue

Celeste Natalie Alverez

Patrick Jeger

Sabine Hadida Ruah

Rafael Ferritto

Hulya Bayir

Sun-Young Kim

Lalith Palitha Samankumara

Robert Clark

Nikhil Tasker

Tanja Krainz

Julianne Glowacki

Alexander Julian Chatterley

Minh Bao Nguyen

Ettore Rastelli

Yongzhao Yan

Serene Tai

Elizabeth Sharlow

Keita Takubo

Melissa M Sprachman

Seth C Hopkins

Xiang Gao

Q Kevin Fang

Gerard Vockley

Milan Chytil

Al-Walid A Mohsen

Song Li

Carole A Bewley

Michele Heffernan

Raghavan Balachandran

Jianfei Jiang

Christopher James Siviy

Natalia A Belikova

Joshua Pierce

Abhay Sudhir Gokhale

Jon Reeves

Jonathan T Reeves

Athanassios Tzounopoulos

Elizabeth R Sharlow

Kelley E McQueeney

Joseph M Salamoun

Taber Sarah Maskrey

Manwika Charaschanya

Qiming Jane Wang

Minh Mindy Bao Nguyen

Provided herein are compounds useful in the prevention or treatment of ferroptosis in a patient, and methods of preventing or treating ferroptosis, or a treating a condition or disease associated with ferroptosis, such as a patient having a neurodegenerative disease, traumatic brain injury, acute kidney disease, liver injury, ischemia/reperfusion injury, ischemic stroke, intracerebral hemorrhage, liver fibrosis, diabetes, acute myeloid leukemia, age-related macular degeneration, psoriasis, a hemolytic disorder, or an inflammatory disease.

Targeted nitroxide compounds and their use in treating ferroptosis-related diseases

The disclosure provides compounds that inhibit protein tyrosine phosphatase, such as protein tyrosine phosphatase 4 A3 (PTP4A3). The disclosure also provides pharmaceutical compositions, uses, and methods of using the compounds, such as in the treatment of cancers.

In-flow photooxygenation of aminothienopyridinones generates novel PTP4A3 phosphatase inhibitors

A compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of:R—(Z)—(Y)—(R)—X—R—R

Compounds for treating prostate cancer

The disclosure provides compounds that inhibit protein tyrosine phosphatase, such as protein tyrosine phosphatase 4A3 (PTP4A3). The disclosure also provides pharmaceutical compositions, uses, and methods of using the compounds, such as in the treatment of cancers. (I), wherein X is O or NH.

In-flow photooxygenation of aminothienopyridinones generates PTP4A3 phosphatase inhibitors

Methods of treating a patient having an organic acidemia or a defect in mitochondria chain oxidation are provided. The methods comprise treating the patient with an effective amount of a mitochondria-targeting reactive oxygen species scavenger.

Method of treatment of organic acidemias and other mitochondria defects or deficiencies

The present technology is directed to methods of inhibiting or modulating p97 and compounds and compositions useful in such methods. Diseases and conditions that can be treated with the compounds and compositions of the present technology include, but are not limited to, antibacterial infection, antiviral infection, cancer and neurodegenerative disorders susceptible to treatment by inhibition or modulation of p97.

Modulators of p97 AAA ATPase activity

A compound, or a pharmaceutically acceptable salt or ester thereof, according to formula I:R&#x2014;(Z)&#x2014;(Y)&#x2014;(R)&#x2014;(X)&#x2014;R&#x2014;Rwherein Ris aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, S(&#x2550;O), &#x2014;S(&#x2550;O)(&#x2550;O)&#x2014;, or NR, wherein Ris H or alkyl; Ris alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl, alkadienyl, substituted alkadienyl, cycloalkenediyl, substituted cycloalkenediyl, alkatrienyl, substituted alkatrienyl; X is &#x2014;C(&#x2550;O)&#x2014;, &#x2014;S(&#x2550;O)(&#x2550;O)&#x2014;, or &#x2014;N(H)C(&#x2550;O)&#x2014;; Rincludes at least one divalent amino radical; Ris aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; a, b, c, and d independently are 0 or 1.

Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer

A mitochondrial-targeted PARP inhibitor is provided herein, as well as methods of making and using the mitochondrial-targeted PARP inhibitor.

Mitochondrially targeted PARP inhibitor, and uses thereof

The present technology is directed to methods of inhibiting or modulating p97 and compounds and compositions useful in such methods. Diseases and conditions that can be treated with the compounds and compositions of the present technology include, but are not limited to, antibacterial infection, antiviral infection, cancer and neurodegenerative disorders susceptible to treatment by modulation of p97.

1,2,3-triazole inhibitors of P97 AAA ATPase activity

The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier.

Compositions and methods for treatment of inflammatory disorders

Selective potassium channel agonists and methods of use thereof are disclosed. A compound, or a pharmaceutically acceptable salt thereof, having a formula I wherein Ris H or optionally-substituted alkyl; Ris optionally-substituted C-Calkyl or optionally-substituted cyclopropyl; Rand Rare each independently H or optionally-substituted alkyl; Ris H, optionally-substituted alkyl, acyl, or alkoxycarbonyl; Rand Rare each independently H, optionally-substituted alkyl, or Rand Rtogether form a carbocycle; Ris substituted phenyl or optionally-substituted pyridinyl, provided that if Ris substituted phenyl, then Ris optionally-substituted cyclopropyl; and R, Rand Rare each independently H, halo, or optionally-substituted alkyl.

Selective potassium channel agonists

The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.

Phenyl indole allosteric inhibitors of P97 ATPase

The present technology is directed to methods of inhibiting or modulating p97 and compounds and compositions useful in such methods Diseases and conditions that can be treated with the compounds and compositions of the present technology include, but are not limited to, antibacterial infection, antiviral infection, cancer and neurodegenerative disorders susceptible to treatment by inhibition or modulation of p97.

Modulators of P97 AAA ATPase activity

Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.

6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity

Growing community of inventors

Pittsburgh, PA, United States of America

Peter Wipf